Above, we show that by incorporating neuroactive compounds and assessing neurological disease-associated genes utilizing CMAPneuro, we can identify compounds that elicit strong transcriptional effects in SMA patient-specific NGN2 neurons. Here, NEUROG2 is linked to nervous system disorder.